Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Merck develops potent, short-acting, orally active GH secretagogues

March 31, 1999

Potent new SERM related to raloxifene presented at ACS meeting by Lilly

March 31, 1999

Ono discloses PPARgamma modulators for metabolic disorders

March 31, 1999

Postmenopausal syndrome continues as focus of R&D at Lilly

March 31, 1999

Preclinical studies support BM-17.0744 as a potential treatment for metabolic syndrome

March 30, 1999

Hemosol product advances; company receives milestone payment from Fresenius

March 30, 1999

Lilly's new agents for lipid disorders act by increasing HDL cholesterol levels

March 30, 1999

FDA approves Duramed's Cenestin for treatment of menopause symptoms

March 29, 1999

Patent issued to Pfizer for NPY antagonist series

March 29, 1999

Droloxifene plus PGE2 effectively restores and maintains bone mass

March 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...